Frontline Aspacytarabine with Venetoclax for Older/Unfit Patients with Acute Myeloid Leukemia: Preliminary Results of a Phase 1 Study

被引：0

作者：

Altman, Jessica K. ^{[1
]}

Abaza, Yasmin ^{[2
]}

Keng, Michael ^{[3
]}

Maiti, Abhishek ^{[4
]}

Koprivnikar, Jamie ^{[5
]}

Tessler, Shoshi ^{[6
]}

Blumberg, Chen ^{[6
]}

Flaishon, Liat ^{[6
]}

Ben Yakar, Ruth ^{[6
]}

机构：

[1] Northwestern Univ, Chicago, IL 60611 USA

[2] Northwestern Med, Chicago, IL USA

[3] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[6] BioSight Ltd, Tel Aviv, Israel

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Acute myeloid leukemia in the medically unfit elderly patients
Edmund, Joseph
Thaliath, Liz Joemon
Meleveedu, Kapil
LEUKEMIA RESEARCH, 2023, 130
[22] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
Han, Xiao
Song, Qingxiao
Wan, Kai
Zhang, Mengyun
Liu, Xue
Yan, Hongju
Zhang, Cheng
Wen, Qin
Zhang, Xi
BONE MARROW TRANSPLANTATION, 2024, 59 : 176 - 177
[23] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
Liu, Qingyang
Yang, Jingjing
Lv, Lei
Zhang, Xiawei
Li, Meng
Xu, Lingmin
Huang, Sai
Jing, Yu
Dou, Liping
FRONTIERS IN IMMUNOLOGY, 2025, 16
[24] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
Murthy, Guru Subramanian Guru
Saliba, Antoine N.
Szabo, Aniko
Harrington, Alexandra
Abedin, Sameem
Carlson, Karen
Michaelis, Laura
Runaas, Lyndsey
Baim, Arielle
Hinman, Alex
Maldonado-Schmidt, Sonia
Venkatachalam, Annapoorna
Flatten, Karen S.
Peterson, Kevin L.
Schneider, Paula A.
Litzow, Mark
Kaufmann, Scott H.
Atallah, Ehab
HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
[25] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
Wu, Y.
Xu, H.
Zhao, X.
Hong, G.
Liu, J.
Yang, Y.
VALUE IN HEALTH, 2024, 27 (06) : S132 - S132
[26] Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
Gangat, Naseema
Ilyas, Rimal
Johnson, Isla M.
McCullough, Kristen
Al-Kali, Aref
Alkhateeb, Hassan B.
Begna, Kebede H.
Mangaonkar, Abhishek
Litzow, Mark R.
Hogan, William
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Tefferi, Ayalew
HAEMATOLOGICA, 2023, 108 (11) : 3170 - 3174
[27] Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China
Yu, Guopan
Yin, Zhao
Xu, Dan
Jiang, Xuejie
Ye, Jieyu
Zhang, Yu
BLOOD, 2022, 140 : 11740 - 11740
[28] Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
Chen, Tzu-Ting
Lin, Ching-Chan
Lo, Wen-Jyi
Hsieh, Ching-Yun
Lein, Ming-Yu
Lin, Che-Hung
Lin, Chen-Yuan
Bai, Li-Yuan
Chiu, Chang-Fang
Yeh, Su-Peng
CANCERS, 2024, 16 (06)
[29] COSTS PER RESPONDER WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE IN UNFIT PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA IN CHINA
Xu, H.
Zhao, X.
Mo, X.
Zhao, J.
Liu, J.
Yang, Y.
VALUE IN HEALTH, 2024, 27 (06) : S152 - S152
[30] For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious
Krayem, Baher
Frisch, Avraham
Zuckerman, Tsila
Henig, Israel
Yehudai-Ofir, Dana
Nachmias, Boaz
Khatib, Hazim
Haran, Arnon
Aumann, Shlomzion
BLOOD, 2024, 144 : 4269 - 4270

← 1 2 3 4 5 →